# OnCo record nct05968326 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05968326/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05968326", "NCT05968326" ;
  schema:name "A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC"@en ;
  schema:alternateName "IMCODE003"@en ;
  schema:description "A phase 2 trial of Autogene cevumeran and Atezolizumab in pancreatic ductal adenocarcinoma, run by Genentech, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05968326/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05968326> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-10-18" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/> ;
  onco:drugs <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:companies <https://onco.cc/companies/flatiron-health/>, <https://onco.cc/companies/biontech/> ;
  onco:terms <https://onco.cc/terms/pancreatic-trials-open-today/> ;
  onco:trials <https://onco.cc/trials/autogene-cevumeran-phase-1/>, <https://onco.cc/trials/amplify-7p/> .